Tenecteplase

Brand names: Tnkase ยท Active ingredient: Tenecteplase

In short: TNKase is indicated for the treatment of acute ischemic stroke (AIS) in adults. TNKase is indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI) in adults.

Forms & strengthsFor injection: 25 mg or 50 mg as a white to pale yellow lyophilized powder in a single-dose vial for reconstitution with co-packaged Sterile Water for Injection, USP (diluent).
LabelGenentech, Inc.
Label updatedDec 23, 2025

What is Tenecteplase used for?

TNKase is indicated for the treatment of acute ischemic stroke (AIS) in adults.

TNKase is indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI) in adults.

Tenecteplase dosage

Initiate treatment as soon as possible and within 3 hours after the onset of stroke symptoms.

TNKase is for intravenous (IV) administration only, administered as a single bolus over 5 seconds. Individualize dosage based on the patient's weight . The maximum recommended dose is 25 mg (5 mL).

Patient Weight(kg) | TNKase(mg) | Volume TNKase to be administered (mL)

less than 60 kg | 15 mg | 3 mL

60 kg to less than 70 kg | 17.5 mg | 3.5 mL

70 kg to less than 80 kg | 20 mg | 4 mL

80 kg to less than 90 kg | 22.5 mg | 4.5 mL

90 kg or more | 25 mg | 5 mL

During and following TNKase administration for the treatment of acute ischemic stroke, frequently monitor and control blood pressure.

In patients without recent use of oral anticoagulants or heparin, TNKase treatment can be initiated prior to the availability of coagulation study results. If the pretreatment International Normalized Ratio (INR) is greater than 1.7 or the activated partial thromboplastin time (aPTT) is elevated, closely monitor patients .

Initiate treatment as soon as possible after the onset of STEMI symptoms.

TNKase is for intravenous (IV) administration only, administered as a single bolus over 5 seconds. Individualize dosage based on the patient's weight . The maximum recommended dose is 50 mg (10 mL).

Patient Weight(kg) | TNKase(mg) | Volume TNKase to be administered (mL)

less than 60 kg | 30 mg | 6 mL

60 kg to less than 70 kg | 35 mg | 7 mL

70 kg to less than 80 kg | 40 mg | 8 mL

80 kg to less than 90 kg | 45 mg | 9 mL

90 kg or more | 50 mg | 10 mL

Follow the steps below to prepare TNKase for administration:

Only use the supplied Sterile Water for Injection diluent vial for reconstitution as shown below.

TNKase Vial Strength | Sterile Water for Injection Vial Volume

25 mg | 5.2 mL

50 mg | 10 mL

Using a sterile syringe, aseptically withdraw the Sterile Water for Injection from the diluent vial and reconstitute the TNKase vial by directing the stream into the lyophilized powder to obtain a final concentration of 5 mg/mL. Slight foaming upon reconstitution is not unusual; any large bubbles will dissipate if the product is allowed to stand undisturbed for several minutes.

Gently swirl until contents are completely dissolved. DO NOT SHAKE. The reconstituted preparation results in a colorless to pale yellow transparent solution.

Determine the appropriate dose of TNKase and withdraw the required volume (in milliliters) from the reconstituted vial into the syringe. Discard any unused solution.

Follow the steps below for administration of TNKase:

Visually inspect the reconstituted product in the syringe for particulate matter and discoloration prior to administration.

Precipitation may occur when TNKase is administered in an intravenous line containing dextrose. โ€ฆ

How to take Tenecteplase โ€” instructions & advice from the label

Bleeding

Inform patients that bleeding can occur 1 or more days after administration of TNKase . Instruct patients to contact a healthcare provider if they experience signs or symptoms consistent with bleeding (e.g., unusual bruising; pink or brown urine; red, black, or tarry stools; coughing up blood; vomiting blood or blood that looks like coffee grounds) or symptoms of a stroke.

Warnings & precautions

Do not take this medicine if: AIS and Acute STEMI

TNKase is contraindicated in any patients with:

Active internal bleeding

Intracranial or intraspinal surgery or trauma within 2 months

Known bleeding diathesis

Current severe uncontrolled hypertension

Presence of intracranial conditions that may increase the risk of bleeding (e.g., intracranial neoplasm, arteriovenous malformation, or aneurysm)

AIS

TNKase is also contraindicated in patients for the treatment of AIS with:

Active intracranial hemorrhage

Acute STEMI

TNKase is also contraindicated in patients for the treatment of STEMI with:

History of intracranial hemorrhage

History of ischemic stroke within 3 months

TNKase can cause significant, sometimes fatal, internal or external bleeding, especially at arterial and venous puncture sites. Concomitant use of other drugs that impair hemostasis increases the risk of bleeding. Avoid intramuscular injections and trauma to the patient while on TNKase. Perform arterial and venous punctures carefully and only as required. To minimize bleeding from noncompressible sites, avoid internal jugular and subclavian venous punctures. If an arterial puncture is necessary during TNKase administration, use an upper extremity vessel that is accessible to manual compression, apply pressure for at least 30 minutes, and monitor the puncture site closely.

Should serious bleeding that is not controlled by local pressure occur, discontinue any concomitant heparin or antiplatelet agents immediately and treat appropriately. Because of the higher risk of intracranial hemorrhage in patients treated for acute ischemic stroke, limit treatment to facilities that can provide timely access to appropriate evaluation and management of intracranial hemorrhage. โ€ฆ

Tenecteplase side effects

The following clinically significant adverse reactions are discussed in other sections of the label:

Bleeding

Hypersensitivity

Thromboembolism

Cholesterol Embolization

Arrhythmias

Increased Risk of Heart Failure and Recurrent Ischemia when used with Planned Percutaneous Coronary Intervention (PCI) in STEMI

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most frequent adverse reaction associated with TNKase in all approved indications is bleeding.

Acute Ischemic Stroke

In Trial 1, the safety of TNKase for the treatment of acute ischemic stroke (AIS) was evaluated in 592 patients who received TNKase at the recommended dosage within 0 to 3 hours of the onset of stroke symptoms (Alteplase compared to Tenecteplase (AcT); Trial 1) .

Table 3 describes the incidence of adverse reactions in patients with AIS in Trial 1.

Adverse Reaction | TNKaseN=592% | ActivaseN= 555%

Death | 15.0 | 15.0

Symptomatic intracerebral hemorrhageintracerebral hemorrhage that, in the opinion of the investigator, was temporally related to and directly responsible for worsening of the neurological condition | 3.4 | 3.1

Extracranial (peripheral) bleeding requiring blood transfusion | 1.0 | 0.7

Orolingual angioedema | 1.0 | 1.4

Drug interactions

During TNKase therapy, results of coagulation tests and/or measures of fibrinolytic activity may be unreliable unless specific precautions are taken to prevent in vitro artifacts. Tenecteplase is an enzyme that, when present in blood in pharmacologic concentrations, remains active under in vitro conditions. This can lead to degradation of fibrinogen in blood samples removed for analysis.

About this medicine

Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using a mammalian cell line (Chinese Hamster Ovary cells). Tenecteplase is a 527-amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296โ€“299 in the protease domain. It has a molecular weight of 58,742 daltons. Biological potency is determined by an in vitro clot lysis assay and is expressed in tenecteplase specific units. The specific activity of tenecteplase has been defined as 200 units/mg.

TNKase (tenecteplase) for injection is a sterile, white to pale yellow, lyophilized powder for intravenous bolus administration after reconstitution with Sterile Water for Injection, USP. โ€ฆ

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label โ€” it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e647640d-c395-4b4b-a0be-1162f9c21d84. Read the full official label on DailyMed.

Related medicines

Rosuvastatin Semaglutide Hydrochlorothiazide Apixaban Simvastatin Empagliflozin Furosemide Carvedilol